is farxiga a glp 1 agonist GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Frontiers | Mini Review: Effect

Description

and 10% in the rest of the world are likely to be treated with GLP-1 therapies by 2035, up from approximately 6% in the U.S

The FDA granted both Fast Track and Breakthrough Therapy designations, indicating regulatory priority

however, their administration is frequently accompanied by adverse events, predominantly gastrointestinal.218,219 Specifically, GLP-1RAs have been strongly linked to gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, with incidence rates influenced by dosage and concomitant therapies.78 Moreover, the use of GLP-1RAs may be associated with an elevated risk of pancreatitis and thyroid-related disorders, although these associations have not been definitively established.220 Analysis of data from the US Food and Drug Administration Adverse Event Reporting System revealed that GLP-1RAs, particularly semaglutide and exenatide, are significantly correlated with gastrointestinal adverse events, including nausea, vomiting, delayed gastric emptying, and pancreatitis.221 Dual receptor agonists targeting GLP-1 and GIP, such as tirzepatide, have also exhibited promising efficacy in diabetes management, notably in terms of weight reduction and glycemic control

GLP-1 plays several important roles

This explains why the magnitude is smaller than retatrutide, which adds direct glucagon receptor-mediated cardiac effects on top of the indirect GLP-1 effects